Vivek Subbiah: A real-life superhero
Vivek Subbiah shared on LinkedIn:
“Want to meet a real-life superhero? Such a delight meeting Mike, my superhero at Sarah Cannon Research Institute!
Thanks to real-life superheroes like Mike for enrolling & volunteering in the CRISPR gene therapy clinical trial for sickle cell disease.
FDA approved this groundbreaking gene therapy for sickle cell disease!
This is the WHY we do what we do – to make life-changing breakthroughs possible!
Today Mike & I discussed how to motivate patients to consider Precision Medicine Clinical trials.
Source: Vivek Subbiah/LinkedIn
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023